Table 4.

Mean ± SD pharmacokinetic parameters for saquinavir during the placebo and the stiripentol phases.

	Period Placebo	Stiripentol		95% confidence interval on differences
Tmax (h)	1.2 ± 0.6	0.92 ± 0.2	NS	0, 0*
Cmax (ng ml−1)	149.3 ± 83.2	149.7 ± 82.4	–
log Cmax	4.86 ± 0.58	4.84 ± 0.65	NS	−39.8, +39.8†
AUC (ng h ml−1)	229.4 ± 131.8	269.0 ± 189.0	–
log AUC	5.23 ± 0.75	5.31 ± 0.84	NS	−33.2, +112†
CL/F (l h−1)	1.90 ± 1.12	2.43 ± 1.90	NS	−0.873, +1.59†
t1/2 (h)	1.12 ± 0.65	1.44 ± 0.93	NS	−0.33, +0.97†

AUC, Area under the plasma concentration-time curve from 0 to 12 h; C_max, maximum plasma concentration; t_max, time to reach C_max; CL/F, apparent clearance; t_1/2, half-life; NS, not significant.

^*Binomial confidence interval.

^†Student's confidence interval.